Global Blood Plasma Fractionation Market Growth 2023-2029

Global Blood Plasma Fractionation Market Growth 2023-2029

Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation.

LPI (LP Information)' newest research report, the “Blood Plasma Fractionation Industry Forecast” looks at past sales and reviews total world Blood Plasma Fractionation sales in 2022, providing a comprehensive analysis by region and market sector of projected Blood Plasma Fractionation sales for 2023 through 2029. With Blood Plasma Fractionation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Blood Plasma Fractionation industry.

This Insight Report provides a comprehensive analysis of the global Blood Plasma Fractionation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Blood Plasma Fractionation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Blood Plasma Fractionation market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Blood Plasma Fractionation and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Blood Plasma Fractionation.

The global Blood Plasma Fractionation market size is projected to grow from US$ 27700 million in 2022 to US$ 47220 million in 2029; it is expected to grow at a CAGR of 47220 from 2023 to 2029.

Global key blood plasma fractionation players include CSL, Grifols and Takeda etc. The top 3 companies hold a share about 55%. North America is the largest market with a share about 40%, followed by Asia-Pacific and Europe.

In terms of product, Immune Globulin is the largest segment with a share about 50%. And in terms of applications, the largest application is hospital with a share about 70%.

This report presents a comprehensive overview, market shares, and growth opportunities of Blood Plasma Fractionation market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Immune Globulin
Coagulation Factor
Albumin
Other

Segmentation by application
Hospital
Retail Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Blood Plasma Fractionation market?

What factors are driving Blood Plasma Fractionation market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Blood Plasma Fractionation market opportunities vary by end market size?

How does Blood Plasma Fractionation break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.